Database : HANSEN
Search on : ANTITUBERCULOSOS [Subject descriptor]
References found : 15 [refine]
Displaying: 1 .. 15   in format [Detailed]

page 1 de 1

  1 / 15 HANSEN  
              next record last record
select
to print
Id:18203
Author:Anon
Title:The US-Japan Cooperative Medical Science Program Tuberculosis and leprosy Panel's 36th Annual Research Conference, New Orleans, Louisiana, USA, 15-17 July 2001 ..-
Source:s.l; s.n; 2002. 23 p. .
Conference:Present in: Leprosy Panel annual research conference, 36, New Orleans, 15-17 july 2001.
Descriptors:MYCOBACTERIUM/clas
MYCOBACTERIUM/cresc
MYCOBACTERIUM/imunol
MYCOBACTERIUM/patogen
MICOBACTERIAS ATIPICAS/cresc
MICOBACTERIAS ATIPICAS/imunol
MICOBACTERIAS ATIPICAS/isol
MICOBACTERIAS ATIPICAS/metab
MICOBACTERIAS ATIPICAS/fisiol
MICOBACTERIAS ATIPICAS/patogen
MYCOBACTERIUM AVIUM/cresc
MYCOBACTERIUM AVIUM/imunol
MYCOBACTERIUM AVIUM/patogen
MYCOBACTERIUM BOVIS/imunol
MYCOBACTERIUM BOVIS/patogen
MYCOBACTERIUM LEPRAE/imunol
MYCOBACTERIUM LEPRAE/patogen
MYCOBACTERIUM TUBERCULOSIS/cresc
MYCOBACTERIUM TUBERCULOSIS/imunol
MYCOBACTERIUM TUBERCULOSIS/isol
MYCOBACTERIUM TUBERCULOSIS/patogen
ANTITUBERCULOSOS/admin
ANTITUBERCULOSOS/ef adv
ANTITUBERCULOSOS/uso terap
COOPERACAO INTERNACIONAL
 COOPERACAO TECNICA
 VACINA BCG/admin
Limits:HUMANO
ANIMAL
Location:BR191.1; 09068/s


  2 / 15 HANSEN  
              first record previous record next record last record
select
to print
Id:17312
Author:Kalk, Andreas; Konig, Jurgen; Van Wijnen, Ary; Wiegandt, Axel
Title:Drug packaging: what can TB learn from leprosy control? ..-
Source:s.l; s.n; 2003. 1 p. .
Descriptors:Antituberculosos/*PD/TU
Controle de Doenças Transmissíveis/*
Sensibilidade e Especificidade
Tuberculose Pulmonar/DI/*DT
Limits:Estudo Comparativo
Embalagem de Medicamentos/*
Feminino
Humano
Masculino
Location:BR191.1; 01753/s


  3 / 15 HANSEN  
              first record previous record next record last record
select
to print
Id:17287
Author:Engers, H; Morel, C. M
Title:Leprosy ..-
Source:s.l; s.n; 2003. 2 p. mapas.
Descriptors:Antituberculosos/TU
Predisposição Genética para Doença
Hanseníase/*/DI/DT/EP/GE
Mycobacterium leprae/GE
Organização Mundial da Saúde
Limits:Humano
Location:BR191.1; 00252/s


  4 / 15 HANSEN  
              first record previous record next record last record
select
to print
Id:13713
Author:Tomimori-Yamashita, Jane; Maeda, Solange M; Sunderkötter, Cord; Kaminsky, Silvia K; Michalany, Nilceo S; Rotta, Osmar; Castro, Raimundo M
Title:Leukomelanodermic leprosy ..-
Source:s.l; s.n; 2002. 3 p. ilus.
Abstract:A 39-year-old woman presented with a 6-year history of asymptomatic macules on her back. The patient had no other complaints, and she did not report any case of infectious disease in her family. Examination revealed hyperpigmented macules, presenting irregular edges but with a sharp demarcation, on the midline of the back from the cervical to the lumbar region. Within these hyperpigmented areas, islands of normal appearing skin were observed. There were also some hypopigmented macules on the lateral and posterior aspects of the trunk (Fig. 1). The patient presented thickening of the left ulnar nerve and sensory loss to temperature on the lateral aspect of the left arm. Biopsy specimens were obtained from the hyper- and hypopigmented areas. In the hyperpigmented macule, the biopsy revealed focal areas of hypomelanosis in the epidermis and the presence of melanophages in the superficial dermis, but no acid-fast bacilli were found (Fig. 2a). The Masson-Fontana stain showed an evident pigmentary incontinence (Fig. 2b). The biopsy obtained from the hypopigmented lesion also revealed focal areas of hypomelanosis, but in the superficial dermis an infiltrate of foamy macrophages was observed, as typically found in lepromatous leprosy (Fig. 3a); acid-fast bacilli were found by Fite-Faraco stain. The focal hypomelanosis was confirmed by Masson-Fontana stain (Fig. 3b). Mitsuda's reaction in this patient was negative and slit-skin smears (cutaneous lesion, earlobes, elbows, and knees) were negative for acid-fast bacilli. The patient was treated with multidrug therapy for multibacillary leprosy: rifampin, 600 mg once monthly (supervised), clofazimine, 300 mg once monthly (supervised), dapsone, 100 mg daily, and clofazimine, 50 mg daily, all given for 2 years. After 7 months of treatment, the hypopigmented lesions diminished and the hyperpigmented lesions improved after 2 years of treatment and the sensory loss to temperature was restored. (AU).
Descriptors:ANTITUBERCULOSOS/TU
QUIMIOTERAPIA COMBINADA
HIPERPIGMENTACAO/PA
HIPOPIGMENTACAO/PA
HANSENIASE VIRCHOWIANA/DT/*PA
MELANOSE/PA
Limits:ADULTO
RELATO DE CASO
FEMININO
HUMANO
Location:BR191.1; 09076/s


  5 / 15 HANSEN  
              first record previous record next record last record
select
to print
Id:13668
Author:Newton, Sandra M; Lau, Clara; Gurcha, Sudagar S; Besra, Gurdyal S; Wright, Colin W
Title:The evaluation of forty-three plant species for in vitro antimycobacterial activities; isolation of active constituents from Psoralea corylifolia and Sanguinaria canadensis ..-
Source:s.l; s.n; 2002. 11 p. ilus, tab.
Abstract:Extracts from forty-three plant species were selected on account of reported traditional uses for the treatment of TB and/or leprosy. These were assayed for antimycobacterial activities. A simple in vitro screening assay was employed using two model species of mycobacteria, M. aurum and M. smegmatis. Crude methanolic extracts from three of the plants, C. mukul, P. corylifolia and S. canadensis, were found to have significant antimycobacterial activity against M. aurum only (MIC=62.5 microg/ml). Bioassay guided fractionation led to the isolation of two known benzophenanthridine alkaloids, sanguinarine (1) and chelerythrine (2), from the roots S. canadensis and the known phenolic meroterpene, bakuchiol (3) from the seeds of P. corylifolia. The fractionation of the resin of C. mukul lead to a decrease in antimycobacterial activity and hence further work was not pursued. Compound (2) was the most active against M. aurum and M. smegmatis (IC(50)=7.30 microg/ml [19.02 microM] and 29.0 microg/ml [75.56 microM], respectively). M. aurum was the most susceptible organism to all three compounds. No significant difference in antimycobacterial activity was observed when the two alkaloids were tested for activity in media of differing pH values. The activities of the pure compounds against M. aurum were comparable with those against M. bovis BCG with compound (2) being the most active (M. bovis BCG, IC(50)=14.3 microg/ml [37.3 microM]). These results support the use of these plants in traditional medicine. (AU).
Descriptors:ANTITUBERCULOSOS/isol
ANTITUBERCULOSOS/uso terap
AVALIACAO DE MEDICAMENTOS/métodos
HANSENOSTATICOS/isol
HANSENOSTATICOS/uso terap
MYCOBACTERIUM/ef drogas
EXTRATOS VEGETAIS/uso terap
MEDICINA TRADICIONAL
FITOTERAPIA
Psoralea
Limits:HUMANO
SUPPORT, NON-U.S. GOV'T
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 09050/s


  6 / 15 HANSEN  
              first record previous record next record last record
select
to print
Id:13632
Author:Abate, Getahun
Title:Drug-resistant tuberculosis in Ethiopia: problem scenarios and recommendation ..-
Source:s.l; s.n; 2002. 8 p. tab.
Abstract:Tuberculosis (TB) is a major public health problem in Ethiopia. This review is prepared to indicate possible future challenges related to tuberculosis control and it includes previous reports of drug-resistant surveys in Ethiopia. Drug-resistant TB, both initial and acquired, was reported from different regions of the country. In studies from 1984 to 2001, the initial resistance to isoniazid ranges from 2 per cent to 21 per cent and initial resistance to streptomycin ranges from 2 to 20 per cent. Multidrug-resistance (MDR) TB defined as resistance to at least isoniazid and rifampicin was also reported in about 1.2 per cent of new cases and 12 per cent of re-treatment cases. In all studies which included ethambutol susceptibility test, ethambutol resistance is either nil or very low (below 0.5 per cent). All MDR isolates were susceptible to ethambutol. Treatment and re-treatment regimens recommended by the National TB/Leprosy Control Program could be effective on all cases other than those with MDR-TB. MDR-TB is difficult to cure. Therefore, special emphasis should be given to control the spread of MDR-TB. Lack of control efforts may lead to the increased resistance to both first- and second-line drugs. A well supported and controlled special treatment unit, which uses both first-line and second-line drugs is required for a proper management of these cases and for effective control of the spread of MDR-TB. A uniform susceptibility to ethambutol can be taken as an advantage to develop standard low-cost re-treatment regimen for MDR-TB patients. (AU).
Descriptors:ANTITUBERCULOSOS/uso terap
ETIOPIA/epidemiol
MYCOBACTERIUM TUBERCULOSIS/ef drogas
TUBERCULOSE RESISTENTE A MULTIPLAS DROGAS/quimioter
TUBERCULOSE RESISTENTE A MULTIPLAS DROGAS/epidemiol
Limits:HUMANO
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 09041/s


  7 / 15 HANSEN  
              first record previous record next record last record
select
to print
Id:13292
Author:Opromolla, Diltor Vladimir Araujo
Title:Results obtained with morphazinamide in the treatment of leprosy ..-
Source:s.l; s.n; 1966. 15 p. ilus, tab, graf.
Abstract:The results obtained with morphazinamide in a group of patients with lepromatous leprosy are presented. The drug was administered at the rate of 2gm daily for 6 months Clinically, the drug proved of value in treatment of leprosy. The results of bacilloscopic studies and histologic examinations were favorable, but insufficient to confirm the clinical impression The drug was perfectly tolerated It is recommended that other hospitals and institutions conduct trials with morphazinamide in order to rech final conclusions as to the drug´s antileprotic action, the appropriate dosage and duration of treatment, toleration, and the possibility of using morphazinamide in association with other suitable drugs.(AU).
Descriptors:HANSENIASE/quimioter
ANTITUBERCULOSOS/uso terap
PIRAZINAS/uso terap
Limits:HUMANO
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 00595/s


  8 / 15 HANSEN  
              first record previous record next record last record
select
to print
Id:13192
Author:Opromolla, Diltor Vladimir Araujo
Title:Results obtained with morphazinamide in the treatment of leprosy ..-
Source:s.l; s.n; 1966. 15 p. tab, graf, ilus.
Abstract:The results obtained with morphazinamide in a group of patients with lepromatous leprosy are presented. The drug was administered at the rate of 2 gm daily for 6 months. Clinically, the group proved of value in the treatment of leprosy. The results of bacilloscopic studies and histologic examinations were favorable, but insufficient to confirm the clinical impression. The drug was perfectly tolerated. It is recommended that other hospitals and institutions conduct clinical trials with morphazinamide in order to reach final conclusions as to the drug's antileprotic action, the appropriate dosage and duration of treatment, toleration, and the possibility of using morphazinamide in association with other suitable drugs. (AU).
Descriptors:HANSENIASE/quimioter
PIRAZINAS/uso terap
ANTITUBERCULOSOS/uso terap
Limits:HUMANO
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 00595/s


  9 / 15 HANSEN  
              first record previous record next record last record
select
to print
Id:12309
Author:Kang, Tae-Jin; You, Ji-Chang; Chae, Gue-Tae
Title:Identification of catalase-like activity from mucobacterium leprae and the relationship between catalase and isonicotinic acid hydrazide (INH) ..-
Source:s.l; s.n; 2001. 7 p. ilus, tab, graf.
Descriptors:SULFATO DE AMONIO
ANTITUBERCULOSOS
SEQUENCIA DE BASES
BENZIDINAS
CATALASE
CATALASE
PRIMERS DO DNA
DNA COMPLEMENTAR
ELETROFORESE EM GEL DE AGAR
PEROXIDO DE HIDROGENIO
ISONIAZIDA
HANSENIASE
HANSENIASE
MACROFAGOS PERITONEAIS
CAMUNDONGOS
CAMUNDONGOS ENDOGAMICOS BALB C
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
PEROXIDASE
 PEROXIDASES
 PEROXIDASES
 REAÇAO EM CADEIA POR POLIMERASE
 DNA POLIMERASE DIRIGIDO POR RNA
 CONTAGEM DE CINTILAÇAO
 HOMOLOGIA DE SEQUENCIA DO ACIDO NUCLÉICO
 ESPECTROFOTOMETRIA
Location:BR191.1; 08638/s


  10 / 15 HANSEN  
              first record previous record next record last record
select
to print
Id:11495
Author:Kang, Tae-Jin; You, Ji-Chang; Chae, Gue-Tae
Title:Identification of catalase like activity from mycobacterium leprae and the relationship between catalase and isonicotinic acid hydrazide (INH) ..-
Source:s.l; s.n; 2001. 7 p. ilus, tab, graf.
Descriptors:HANSENIASE
HANSENIASE
ANTITUBERCULOSOS
BENZIDINAS
CATALASE
CATALASE
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
PRIMERS DO DNA
DNA COMPLEMENTAR
ELETROFORESE EM GEL DE AGAR
PEROXIDO DE HIDROGENIO
ISONIAZIDA
MACROFAGOS PERITONEAIS
PEROXIDASE
PEROXIDASE
REAÇAO EM CADEIA POR POLIMERASE
CONTAGEM DE CINTILAÇAO
HOMOLOGIA DE SEQUENCIA DO ACIDO NUCLÉICO
Location:BR191.1; 08385/s


  11 / 15 HANSEN  
              first record previous record next record last record
select
to print
Id:11455
Author:Skamene, Emil; Schurr, Erwin; Gros, Philippe
Title:Infection genomics: Nramp1 as a major determinant of natural resistance to intracellular infections ..-
Source:s.l; s.n; 1998. 13 p. .
Descriptors:ALELOS
ANTITUBERCULOSOS
INFECÇOES BACTERIANAS
INFECÇOES BACTERIANAS
INFECÇOES BACTERIANAS
INFECÇOES BACTERIANAS
PROTEINAS DE TRANSPORTE
SURTOS DE DOENÇAS
SUSCETIBILIDADE A DOENÇA
GENOMA BACTERIANO
GENOMA HUMANO
GENOMA DE PROTOZOARIO
LEISHMANIOSE
LEISHMANIOSE
IMUNIDADE NATURAL
LEPROSTATICOS
HANSENIASE
HANSENIASE
HANSENIASE
HANSENIASE
LIGAÇAO (GENÉTICA)
MACROFAGOS
PROTEINAS DA MEMBRANA
CAMUNDONGOS
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM TUBERCULOSIS
MYCOBACTERIUM TUBERCULOSIS
INFECÇOES POR SALMONELLA
INFECÇOES POR SALMONELLA
TUBERCULOSE
TUBERCULOSE
TUBERCULOSE
TUBERCULOSE
Predisposição Genética para Doença
Limits:ESTUDO COMPARATIVO
ANIMAL
Location:BR191.1; 08338/s


  12 / 15 HANSEN  
              first record previous record next record last record
select
to print
Id:10251
Author:Bermudez, Luiz E
Title:Use of liposome preparation to treat mycobacterial infections ..-
Source:s.l; s.n; 1994. 6 p. .
Descriptors:INFECÇOES OPORTUNISTAS RELACIONADAS COM A AIDS
INFECÇOES OPORTUNISTAS RELACIONADAS COM A AIDS
ANTIINFECCIOSOS
ANTITUBERCULOSOS
PORTADORES DE DROGAS
HANSENIASE
LIPOSSOMOS
MICOBACTERIOSE
MICOBACTERIOSE
INFECÇAO POR MYCOBACTERIUM AVIUM-INTRACELLULARE
TUBERCULOSE
TUBERCULOSE RESISTENTE A MULTIPLAS DROGAS
Location:BR191.1; 06961/s


  13 / 15 HANSEN  
              first record previous record next record last record
select
to print
Id:10247
Author:Fegan, David; Glennon, Jacqueline
Title:Use of steroids in dermatological emergencies ..-
Source:s.l; s.n; 1993. 3 p. ilus.
Descriptors:ANTIINFLAMATORIOS ESTEROIDES
ANTITUBERCULOSOS
DAPSONA
SERVIÇOS MÉDICOS DE EMERGENCIA
ERITEMA MULTIFORME
ERITEMA MULTIFORME
HANSENIASE DIMORFA
PENFIGO
PREDNISOLONA
DERMATOPATIAS
Location:BR191.1; 06957/s


  14 / 15 HANSEN  
              first record previous record next record last record
select
to print
Id:10167
Author:Bermudez, Luiz E
Title:Use of liposome preparation to treat mycobacterial infections ..-
Source:s.l; s.n; 1994. 6 p. .
Descriptors:HANSENIASE
INFECÇOES OPORTUNISTAS RELACIONADAS COM A AIDS
INFECÇOES OPORTUNISTAS RELACIONADAS COM A AIDS
ANTIINFECCIOSOS
ANTITUBERCULOSOS
PORTADORES DE DROGAS
LIPOSSOMOS
MICOBACTERIOSE
INFECÇAO POR MYCOBACTERIUM AVIUM-INTRACELLULARE
TUBERCULOSE
TUBERCULOSE RESISTENTE A MULTIPLAS DROGAS
Location:BR191.1; 07080/s


  15 / 15 HANSEN  
              first record previous record
select
to print
Id:3809
Author:David, Hugo L; Clavel, Sabine; Clement, Françoise; Moniz-Pereira, José
Title:Effects of antituberculosis and antileprosy drugs on mycobacteriophage D29 growth ..-
Source:s.l; s.n; 1980. 2 p. graf, tab.
Descriptors:MYCOBACTERIUM
ANTITUBERCULOSOS
ANTIVIRAIS
LEPROSTATICOS
TESTES DE SENSIBILIDADE MICROBIANA
MICOBACTERIOFAGOS
MICOBACTERIOFAGOS
Location:BR191.1; 02649/s



page 1 de 1
   


Refine the search
  Database : HANSEN Advanced form   
Search for : Free form   

    Search in field  
1  
2
3
 
           



Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO
Latin American and Caribbean Center on Health Sciences Information